Kalaris Therapeutics, Inc.
KLRS
$4.16
$0.081.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -8.58% | 15.94% | -4.79% | -11.32% | 53.71% |
| Total Depreciation and Amortization | 0.00% | 233.33% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -100.00% | -99.48% |
| Total Other Non-Cash Items | 593.10% | -89.77% | -4.06% | 165.02% | 101.08% |
| Change in Net Operating Assets | -139.58% | 32,022.22% | 99.49% | -175.87% | 320.90% |
| Cash from Operations | -64.11% | 37.73% | 9.62% | -68.51% | 5.22% |
| Capital Expenditure | -- | 90.71% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -435.67% | 143.45% | -- | -- | -- |
| Cash from Investing | -436.05% | 143.17% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -24.80% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.82% | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -130.82% | -- | -- | -100.00% | 4,260.43% |
| Cash from Financing | -103.55% | -- | -- | -100.00% | 1,315.69% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -214.30% | 220.91% | -267.17% | -112.56% | 36,532.85% |